Patent classifications
C07D207/263
HETEROCYCLIC NMDA ANTAGONISTS
A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.
HETEROCYCLIC NMDA ANTAGONISTS
A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.
Neprilysin inhibitors
In one aspect, the invention relates to compounds having the formula: ##STR00001##
where R.sup.1-R.sup.6, a, b, and Z are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
Neprilysin inhibitors
In one aspect, the invention relates to compounds having the formula: ##STR00001##
where R.sup.1-R.sup.6, a, b, and Z are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF
The disclosure provides compounds of formula II with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease.
##STR00001##
QUATERNARY HETEROATOM CONTAINING COMPOUNDS
The invention provides heterocyclic compounds with quaternary centers and methods of preparing compounds. Methods include the method for the preparation of a compound of Formula (II):
##STR00001##
comprising treating a compound of Formula (I):
##STR00002##
with a transition metal catalyst and under alkylation conditions as valence and stability permit.
QUATERNARY HETEROATOM CONTAINING COMPOUNDS
The invention provides heterocyclic compounds with quaternary centers and methods of preparing compounds. Methods include the method for the preparation of a compound of Formula (II):
##STR00001##
comprising treating a compound of Formula (I):
##STR00002##
with a transition metal catalyst and under alkylation conditions as valence and stability permit.
HETEROCYCLIC NMDA ANTAGONISTS
A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.
##STR00001##
HETEROCYCLIC NMDA ANTAGONISTS
A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.
##STR00001##
WATER-SOLUBLE, MODIFIED AMINO ACID DERIVATIVES FOR TREATMENT OF NEUROLOGICAL DISEASES, AND SELECTED PSYCHIATRIC DISORDERS
Water-soluble analogs of compounds intended for the treatment of neurological diseases, epilepsy, neuropathic pain and migraine, and psychiatric disorders, including anxiety and depression, especially suitable for the preparation of oral or parenteral drug forms, are disclosed.
##STR00001##